1087 related articles for article (PubMed ID: 10703393)
1. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
[TBL] [Abstract][Full Text] [Related]
5. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
Stegall MD; Simon M; Wachs ME; Chan L; Nolan C; Kam I
Transplantation; 1997 Dec; 64(12):1695-700. PubMed ID: 9422404
[TBL] [Abstract][Full Text] [Related]
10. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
15. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
[TBL] [Abstract][Full Text] [Related]
17. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations.
Kim YS; Moon JI; Kim SI; Park K
Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420
[TBL] [Abstract][Full Text] [Related]
18. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
[TBL] [Abstract][Full Text] [Related]
20. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]